<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03682419</url>
  </required_header>
  <id_info>
    <org_study_id>D-CLIN-PROT-00001</org_study_id>
    <nct_id>NCT03682419</nct_id>
  </id_info>
  <brief_title>Evaluation of Precision and Accuracy of INR Measurements in a Point of Care Device (OPTIMAL)</brief_title>
  <acronym>OPTIMAL</acronym>
  <official_title>Evaluation of the Precision and Accuracy of International Normalised Ratio (INR) Measurements as Assessed by the LumiraDx Instrument in a Professional Point of Care Setting With Multiple Operators</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LumiraDx UK Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LumiraDx UK Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparison of capillary whole blood INR determined by LumiraDx Instrument to venous plasma&#xD;
      INR determined by laboratory reference method (IL ACL ELITE PRO) for method comparison and&#xD;
      assessment of accuracy and bias by regression analysis and other analytical methods.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A performance evaluation study designed to assess the precision and accuracy of the LumiraDx&#xD;
      Instrument, a point of care in vitro diagnostic system employing a portable diagnostic meter&#xD;
      in conjunction with single use analyte test strips, for the quantitative determination of&#xD;
      Prothrombin Time expressed as International Normalised Ratio (INR), as sampled from&#xD;
      individuals evaluated for INR at the point of care (POC).&#xD;
&#xD;
      The accuracy of the LumiraDx Instrument INR results will be assessed by, in the first&#xD;
      instance, comparison to the INR results obtained from the same individuals as analysed by&#xD;
      trained laboratory professionals using the paired venous plasma samples in the reference&#xD;
      device IL ACL ELITE PRO Coagulation Analyzer. The accuracy of INR measurements of capillary&#xD;
      whole blood across the range of haematocrit (25% - 55%) will be assessed using paired&#xD;
      haematocrit results obtained from the HemoCue Hb 201+ on venous whole blood. The results of&#xD;
      these evaluations are intended to be used for regulatory filings for the LumiraDx Instrument&#xD;
      and LumiraDx INR test as an in vitro diagnostic test in the European Union (EU) and other&#xD;
      relevant geographies. For information only, the accuracy of the LumiraDx Instrument INR Test&#xD;
      will also be assessed by comparison to INR results from an alternative point of care&#xD;
      instrument, the Roche Coaguchek PRO II.&#xD;
&#xD;
      Adult males and females currently in receipt of vitamin K antagonist therapy will be included&#xD;
      on the study. Approximately 500 subjects will be recruited to ensure that sufficient suitable&#xD;
      subjects are enrolled and to allow for a small level of exclusions. The power calculation as&#xD;
      well as recommendations of the FDA CLIA Waiver Guidance document (1) requires a minimum of&#xD;
      360 valid subjects in total (inclusive of non-therapy subset). A subsection of the subject&#xD;
      population (~50 subjects) will consist of adult males and females who fulfil all other study&#xD;
      inclusion criteria but are not in receipt of vitamin K antagonist therapy. This will be done&#xD;
      in order to test the lower measurement limit of the LumiraDx Instrument INR test. At the end&#xD;
      of the study the Healthcare Professional will be asked to complete a User Acceptability&#xD;
      Questionnaire which is intended to assess the acceptability of the LumiraDx INR system in&#xD;
      terms of ease of use.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 17, 2018</start_date>
  <completion_date type="Actual">November 23, 2018</completion_date>
  <primary_completion_date type="Actual">November 23, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>A performance evaluation study.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the clinical performance of the LumiraDx instrument</measure>
    <time_frame>8 weeks</time_frame>
    <description>Measurement of INR using Capillary &amp; Venous blood samples</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the accuracy of the LumiraDx instrument</measure>
    <time_frame>8 weeks</time_frame>
    <description>Measurement of INR &amp; Haematocrit using Capillary &amp; Venous blood samples</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">420</enrollment>
  <condition>Deep Vein Thrombosis</condition>
  <condition>Atrial Fibrillation</condition>
  <condition>Post-Myocardial Infarction Syndrome</condition>
  <condition>Pulmonary Embolism</condition>
  <condition>Artificial Heart Device User</condition>
  <condition>Thrombophilia</condition>
  <condition>Antiphospholipid Syndrome</condition>
  <arm_group>
    <arm_group_label>VKA Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single Arm - blood collection by venepuncture and fingerstick in patients undergoing Warfarin Therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-Vka Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single Arm - blood collection by venepuncture and fingerstick in patients not undergoing Warfarin Therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>VKA Patients</intervention_name>
    <description>Venepuncture and capillary blood collection from Patients receiving Warfarin Therapy</description>
    <arm_group_label>VKA Patients</arm_group_label>
    <arm_group_label>non-Vka Patients</arm_group_label>
    <other_name>Fingerstick to collect blood samples from Patients</other_name>
    <other_name>Venepuncture to collect blood samples from Patients</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Non-VKA Patients</intervention_name>
    <description>Venepuncture and capillary blood collection from Patients not receiving Warfarin Therapy</description>
    <arm_group_label>VKA Patients</arm_group_label>
    <arm_group_label>non-Vka Patients</arm_group_label>
    <other_name>Fingerstick to collect blood samples from Patients</other_name>
    <other_name>Venepuncture to collect blood samples from Patients</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria - VKA Therapy Subjects:&#xD;
&#xD;
          -  Persons &gt;18 years of age&#xD;
&#xD;
          -  Willing and able to provide written informed consent and comply with study procedures&#xD;
&#xD;
          -  Currently prescribed vitamin K antagonist therapy&#xD;
&#xD;
          -  Deemed medically appropriate for study participation by the Investigator&#xD;
&#xD;
        Exclusion Criteria - VKA Therapy Subjects:&#xD;
&#xD;
          -  Persons &lt;18 years of age&#xD;
&#xD;
          -  Subject has previously participated in this study&#xD;
&#xD;
          -  Subject is within 4 weeks of first prescription of vitamin K antagonist therapy&#xD;
&#xD;
          -  Confirmed or suspected pregnancy&#xD;
&#xD;
          -  Unwilling or unable to provide written informed consent and comply with study&#xD;
             procedures&#xD;
&#xD;
          -  Vulnerable populations deemed inappropriate for study by the Investigator&#xD;
&#xD;
          -  Deemed medically inappropriate for study by the Investigator (i.e. patients with a&#xD;
             known inherited [e.g. haemophilia or von Willebrand's disease] or acquired [e.g. liver&#xD;
             cirrhosis] condition likely to be associated with a coagulopathy; or patients&#xD;
             receiving non-VKA anticoagulant medications)&#xD;
&#xD;
        Inclusion Criteria - Non-VKA Therapy Subjects:&#xD;
&#xD;
          -  Persons &gt;18 years of age&#xD;
&#xD;
          -  Willing and able to provide written informed consent and comply with study procedures&#xD;
&#xD;
          -  Deemed medically appropriate for study participation by the Investigator&#xD;
&#xD;
        Exclusion Criteria - Non-VKA Therapy Subjects:&#xD;
&#xD;
          -  Persons &lt;18 years of age&#xD;
&#xD;
          -  Subject has previously participated in this study&#xD;
&#xD;
          -  Confirmed or suspected pregnancy&#xD;
&#xD;
          -  Unwilling or unable to provide written informed consent and comply with study&#xD;
             procedures&#xD;
&#xD;
          -  Vulnerable populations deemed inappropriate for study by the Investigator&#xD;
&#xD;
          -  Any persons deemed medically inappropriate for study by the Investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert C Tait, BSc (Hons)</last_name>
    <role>Principal Investigator</role>
    <affiliation>Consultant Haematologist</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Glasgow Royal Infirmary Clinical Research Facility</name>
      <address>
        <city>Glasgow</city>
        <zip>G4 0SF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Golden Jubilee National Hospital</name>
      <address>
        <city>Glasgow</city>
        <zip>G81 4DY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wishaw General Hospital, NHS Lanarkshire</name>
      <address>
        <city>Wishaw</city>
        <zip>ML2 0DP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>September 19, 2018</study_first_submitted>
  <study_first_submitted_qc>September 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2018</study_first_posted>
  <last_update_submitted>February 26, 2019</last_update_submitted>
  <last_update_submitted_qc>February 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
    <mesh_term>Thrombophilia</mesh_term>
    <mesh_term>Antiphospholipid Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

